QIAGEN N.V. Business Summary

QIAGEN N.V. (QGEN) operates as a global leader in "Sample to Insight" solutions, providing a comprehensive portfolio of sample and assay technologies, bioinformatics, and automation systems that transform biological materials into molecular insights. The company generates revenue through a high-margin, recurring model driven by consumables (approximately 80% of sales), supplemented by instrument placements and software-as-a-service (SaaS) through its QIAGEN Digital Insights (QDI) division. As of early 2026, the business is organized into four primary segments: Diagnostic Solutions (38%), Sample Technologies (33%), PCR/Nucleic Acid Amplification (15%), and Genomics/NGS (12%). QIAGEN maintains a dominant market position in latent tuberculosis testing with its QuantiFERON-TB Gold Plus assay and is aggressively expanding its single-cell analysis capabilities following the December 2025 acquisition of Parse Biosciences. Its primary direct competitors include Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, and Bio-Techne, with QIAGEN differentiating itself through specialized niche leadership in sample preparation and integrated diagnostic workflows. Founded in 1984 by a team of researchers including Metin Colpan, Karsten Henco, Jürgen Schumacher, and biophysicist Detlev Riesner, QIAGEN is currently led by Chief Executive Officer Thierry Bernard, who assumed the role in 2020 after a 15-year tenure at bioMérieux and holds degrees from Sciences Po and Harvard Business School. The executive team is anchored by long-standing Chief Financial Officer Roland Sackers, a former Arthur Andersen auditor who has overseen the company’s financial strategy since 2004, and Chief Operating Officer Antonio Santos. Governance is provided by a two-tier board structure chaired by Stephen H. Rusckowski, the former CEO of Quest Diagnostics. In January 2026, the company further strengthened its Supervisory Board by appointing Mark Stevenson, the former COO of Thermo Fisher Scientific, as an independent director. Notable institutional backing remains robust, with approximately 70% of shares held by major entities such as BlackRock and Vanguard, while the company continues to evaluate strategic options amid renewed takeover interest from U.S.-based life science conglomerates.